Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Who Can Benefit: Individuals with a BMI of 30 or higher
Prescribing labels and reconstitution guides typically use IU
Romero-Gomez M, Armstrong MJ, Funuyet-Salas J, Mangla KK, Ladelund S, Sejling AS, et al
Tirzepatide is an approved, extensively studied dual agonist with a proven safety record, commercial availability, and the most comprehensive Phase 3 dataset in the GLP-1 class
doi:10.1089/thy.2023.0506 Lisco G, De Tullio A, Giagulli VA, et al
US$ 28.86
US$ 24.51
US$ 25.07
US$ 23.15
